

IN THE SPECIFICATION:

Page 5: Between the Summary of the Invention and the Detailed Description of the Invention, please insert the following:

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S)

1. Figure 1 illustrates the effect of HP184 on brain damage at 10 and 20 mg/kg iv bolus 1 hour after MCA Occlusion (Example Three).
2. Figure 2 shows the behavioral scores of rats after acute treatment with HP184 (ip administration) following spinal cord compression – (Example Six).
3. Figure 3 shows the behavioral scores of rats after acute treatment with HP184 (po administration) following spinal cord compression – (Example Six)
4. Figure 4 shows the behavioral scores of rats in the Chronic Crush Experiment 25 days after a mild compression injury (Example Six)
5. Figure 5 shows the normalized difference in scoring for rats with a 25-day old mild compression injury (Example Six)
6. Figure 6a shows open field locomotor ability assessment in animals with moderate compression injury (Example Six)
7. Figure 6b shows open field locomotor ability assessment data in animals with moderate compression injury normalized for each rat (Example Six)
8. Figure 7 shows effect of HP184 on demyelinated area at the moderate compression injury site (Example Six)
9. Figure 8 shows the effects of HP184 on bladder contraction frequency (Example 7)
10. Figure 9 shows the effect of HP184 on NO production in mice (Example 8)
11. Figure 10 shows the effect of HP184 in a neuropathic pain model (Example 9)

In the Drawings:

Page 7/11: Please relabel this drawing as Fig. 6b. This drawing is currently labeled as Figure 7.

Page 8/11: Please relabel this drawing as Fig. 7. This drawing is currently labeled as Figure 8.

Page 9/11: Please relabel this drawing as Fig. 8. This drawing is currently labeled as Figure 9.

USAV2001/0002 US NP